265 results about "Obstructive Pulmonary Diseases" patented technology

The invention discloses a chronic obstructive pulmonary disease high risk dynamic assessment model system based on an artificial intelligence algorithm, relates to the technical field of chronic obstructive pulmonary disease high risk assessment, and aims to solve the technical problem that the timeliness and accuracy of an assessment result of an existing assessment model are limited. The medical data acquisition module is used for acquiring medical data of a subject through a wearable device, an electronic medical record system or a manually input multi-source channel, generating standardized preprocessed medical data after performing format cleaning, missing value filling and abnormal value filtering on the data, and transmitting the standardized preprocessed medical data to the memory of the cloud database; and the artificial intelligence dynamic assessment model construction module is used for constructing an artificial intelligence assessment model fusing time sequence characteristics and a nonlinear relationship based on the preprocessed medical data, and generating an intermediate result and a final parameter of risk assessment through multi-level calculation. The method has the advantage that the high risk of chronic obstructive pulmonary disease can be dynamically evaluated in real time.

The present application belongs to the technical field of traditional Chinese medicine, and particularly relates to a traditional Chinese medicine composition for relieving cough and asthma, and a preparation method and application thereof. The traditional Chinese medicine composition comprises, in mass parts, perilla seed 5-15 parts, radish seed 5-15 parts, white mulberry bark 5-15 parts, orange red or processed orange red 5-15 parts, and cassia 5-15 parts. The traditional Chinese medicine composition has the effect of relieving cough and asthma, can effectively improve the clinical symptoms such as cough, expectoration and wheezing of patients with chronic obstructive pulmonary disease, promote lung rehabilitation, improve the dyspnea condition of the patients, and improve the life quality of the patients.

The utility model discloses a rehabilitation training device for nursing chronic obstructive pulmonary disease, a pedaling device comprises a mounting frame and a linkage assembly, and the mounting frame is arranged on the other side of a support frame; the linkage assembly is rotatably arranged in the mounting frame; the breathing device comprises a breathing box, a breathing assembly, a hose and a mask, and the breathing box is arranged on one side of the top of the mounting frame; the breathing assembly is arranged in the breathing box, and the breathing assembly is connected with the linkage assembly; one end of the hose is connected with the breathing assembly; the mask is connected with the other end of the hose; the control system comprises a microprocessor, and the microprocessor is arranged in the breathing box and connected with the breathing assembly. Therefore, the device combines pedaling and breathing training, strengthens lower limb strength and improves the breathing function, the linkage assembly ensures synchronization of the pedaling and breathing training, the training effect is improved, the built-in control system monitors breathing in real time, the training intensity is automatically adjusted, safety and comfort are guaranteed, and the training effectiveness and patient compliance are improved.

An early screening system for chronic obstructive pulmonary disease based on blood routine test data. It belongs to the technical field of digital medical treatment, and specifically relates to the technical field of intelligent early screening of chronic obstructive pulmonary disease. It solves the technical problem that the generalization ability of a COPD prediction model is limited due to differences between different research data sets. The system comprises a data collection module that collects blood routine test data of a plurality of chronic obstructive pulmonary disease patients and blood routine test data of a plurality of normal personnel; a data preprocessing module that performs standardization processing on the blood routine test data to obtain a standardized data set; a screening model training module that trains N classification models using the standardized data set and calculates the prediction accuracy of each classification model; and a screening model application module that obtains the fusion weight of each model by using a normalization processing method based on the prediction accuracy of each classification model, fuses the risk scores predicted by the multiple models, and obtains a final screening result.

The invention relates to the technical field of chronic obstructive pulmonary disease rehabilitation medical equipment and services, discloses a chronic obstructive pulmonary disease multi-mode respiratory training system based on behavioral design science, and aims to solve the technical problems that an existing respiratory training product is poor in patient compliance, poor in user experience and lack of personalized behavior guidance. The system comprises a hardware equipment cluster and a software service platform, a multi-dimensional intervention architecture is constructed based on an FBM behavior model, and closed-loop services of respiratory training, drug management, health monitoring and rehabilitation support are realized through an motivation promotion module, a capability optimization module, a multi-sensory prompt module and a data interaction module. The system effectively stimulates the training enthusiasm of a patient, reduces the operation threshold, improves the training and medication compliance, improves the respiratory function and life quality of the patient, reduces the consumption of medical resources, and has remarkable clinical application value and social and economic benefits through deep fusion of behavioral design and a multi-modal rehabilitation technology.

The present disclosure introduces an AI-based system (100) and method for predicting the risk of acute exacerbation of chronic obstructive pulmonary disease (COPD) over three months. The system interfaces with consumer devices through REST APIs, ensuring secure communication via HTTPS. Client modules collect and pre-process raw data for integrity and compatibility. This data is then sent to the server (104) which is then transmitted to Input module, the input module (112) authenticates and validates it. The module processes personal details, respiratory history, allergies, vaccination and medication history, and demographic data for air quality analysis. The prediction module (116) uses a CART Model with 90% accuracy to evaluate COPD risk. Based on predefined thresholds, the clinical pathway module (118) and risk prediction response module (120) offer personalized treatment protocols and clinical decision support. The system complies with ISO 13485 standards for safety and reliability.

The application belongs to the field of digital medicine, and particularly relates to a chronic obstructive pulmonary disease (COPD) differential system based on digital lung sound, a construction method and application thereof. The system comprises a data acquisition module, a preprocessing module, a conversion module, a data module, a data processing module, a data enhancement training module, a deep learning module, a differential module, a grading module and a display module. Digital lung sound records of candidates are collected, converted into mel spectrograms, and diagnosed by using a deep neural network. The candidates are COPD patients, healthy people, or people suffering from other lung diseases, and the disease grade of the COPD patients is given by a device carrying the differential system. The examination only needs to collect lung sounds in clinical or other places, reduces radiation damage and possible infection risk in the conventional diagnosis process, and provides a scheme for early diagnosis of COPD, and improves the diagnosis efficiency of the respiratory department, especially the COPD disease.

The invention relates to the technical field of medical instruments, and discloses a respiratory efficiency feedback-based chronic obstructive pulmonary disease home rehabilitation device which comprises a respiratory training rehabilitation device body, an extension tube is arranged at the front end of the respiratory training rehabilitation device body, and a respirator is fixedly connected to the end, away from the respiratory training rehabilitation device body, of the extension tube. A feedback assembly is arranged in the middle of the extension pipe, an adjusting assembly is arranged in the feedback assembly, a supplementing assembly is arranged on the side edge of the feedback assembly, the feedback assembly comprises a hollow box fixedly connected to the middle of the extension pipe, a center shaft movably penetrates through the upper portion of the hollow box, and air flow blades are distributed on the outer surface of the center shaft in an annular array mode. By arranging the feedback assembly and the middle of the extension tube, the feedback assembly can be driven to operate in the breathing process of a patient, the feedback effect is achieved through the moving track of the red tying cloth, the feedback situation changes along with the breathing rate of the patient, expiration and inspiration are fed back separately through the one-way bearing, and the feedback effect is more detailed.

The invention discloses a lung disease diagnosis and grading method based on quantitative CT image omics and deep learning. According to the method, through multi-dimensional information integration and model optimization, two core tasks of disease judgment and disease condition grading can be completed at the same time, and comprehensive support is provided for clinical diagnosis and treatment. The model sets feature priorities by referring to clinical diagnosis logic in the training process, the judgment result and the grading standard are completely matched with clinical general specifications, and the model can be directly applied to diagnosis and treatment decision-making without secondary conversion of doctors. After multi-center clinical verification and iterative optimization, the stability and the accuracy of the model are fully guaranteed, subjective errors caused by manual film reading can be effectively reduced, the diagnosis efficiency can be improved, the chronic obstructive pulmonary disease screening capability of primary medical institutions can be remarkably improved, early diagnosis and early treatment of more patients can be helped, and the clinical application prospect is wide. Therefore, the morbidity and disability rate of diseases are reduced, a clinical management path is optimized, and the overall disease burden is relieved.

The invention relates to a crystal form of a compound shown as a formula I or a pharmaceutically acceptable salt thereof and a preparation method of the crystal form of the compound shown as the formula I or the pharmaceutically acceptable salt thereof. The compound of the formula I or the pharmaceutically acceptable salt thereof is used for treating cardiovascular diseases, endothelial dysfunction, diastolic dysfunction, atherosclerosis, hypertension, heart failure, pulmonary arterial hypertension (WHO levels I, II, III, IV), angina pectoris, thrombus, restenosis, myocardial infarction, stroke, cardiac insufficiency, fibrosis, pulmonary hyperplasia, erectile dysfunction, asthma, chronic kidney disease, diabetes, and the like. The composition can be used for treating liver cirrhosis, chronic obstructive pulmonary disease (COPD), acute respiratory distress syndrome, acute lung injury, pulmonary fibrosis, cystic fibrosis or interstitial lung disease.

The invention discloses a specific antibody for detecting cathepsin S, a kit and application. The specific antibody for detecting cathepsin S is prepared by coupling a cathepsin S specific antigen epitope peptide with a carrier protein and then immunizing an animal, and the amino acid sequence of the antigen epitope peptide is at least one of a sequence shown as SEQ ID NO.1 and a sequence shown as SEQ ID NO.2. The specific antibody for detecting cathepsin S can specifically detect cathepsin S, and has the advantages of high sensitivity, good specificity, good repeatability and the like; when being used for auxiliary diagnosis or curative effect evaluation of the chronic obstructive pulmonary disease, the marker has good diagnosis sensitivity, specificity and repeatability, meets clinical application requirements, provides a more accurate and reliable objective index for auxiliary diagnosis, illness monitoring and prognosis evaluation of the chronic obstructive pulmonary disease, and is worthy of popularization and application. The method has important significance and clinical application value for diagnosis and treatment of chronic obstructive pulmonary diseases.

The invention belongs to the field of traditional Chinese medicine biological medicine, and particularly relates to a medicinal and edible traditional Chinese medicine composition and a preparation method, a traditional Chinese medicine preparation and application thereof. The invention provides a medicinal and edible traditional Chinese medicine composition which comprises the following components in parts by weight: ginseng, lily, Chinese yam, angelica sinensis, poria cocos, pericarpium citri reticulatae, ginkgo, radix polygonati officinalis, rhizoma zingiberis and honey-fried licorice root. The preparation method comprises the following steps: mixing the raw materials, adding water for soaking, extracting with water, filtering an extracting solution, concentrating filtrate, and collecting paste to obtain a semi-solid extract or a liquid extract; and further drying the obtained semi-solid extract or liquid extract to obtain the solid extract of the traditional Chinese medicine composition. The traditional Chinese medicine composition provided by the invention adopts an all-medicine-food homologous formula, has no toxic or side effect, is suitable for being taken by various people for a long time, has definite functionality, and is creatively compatible aiming at chronic respiratory system diseases, especially chronic obstructive pulmonary disease in a stable phase complex pathogenesis; the traditional Chinese medicine composition can be applied to health-care products for adjuvant therapy of chronic obstructive pulmonary disease or drugs for treatment of chronic obstructive pulmonary disease.

Administration of pentadecanoylcarnitine or pentadecanoic acid is provided for prevention, management or treatment of aggression, allergies, allergic rhinitis, Alzheimer's disease, anxiety and anxiety disorders, amyotrophic lateral sclerosis, arthritis, asthma, atherosclerosis, attention-deficit hyperactivity disorder, bipoloar disorder, brain damage, cancer, cardiovascular disease, cholestatic pruritis, depression, chronic obstructive pulmonary disease (COPD), cocaine abuse, cough, dermatitis, depression, drug-seeking behavior, gastrointestinal disorders, facial erythema associated with rosacea, glaucoma, hepatic diseases, hyperactive bladder, hypersensitivity disorders, hypertension, impulsivity, inflammation, mental disorders and conditions, metabolic disorders, migraines, nasal and sinus congestion, nausea, neuropathic pain with and symptoms of multiple sclerosis, neurological and neuropsychiatric disorders, obesity, obsessive-compulsive disorders, opioid-induced respiratory depression, osteoarthritis, pain, Parkinson disease, pathological gambling, peptic ulcers, schizophrenia, sleep disorders, spinal cord injury, tardive dyskinesia, tics and behavioral problems with Tourette's syndrome; as well as for supporting appetite, cardiovascular health, hematologic health, memory, metabolic health, mood, prolonged REM sleep, renal health, sexuality, sociability and metabolic, hematological, renal, and weight loss.

The present invention provides, in part, novel small molecule inhibitors of PHD, having a structure according to Formula (I), and sub-formulas thereof: Formula (I) or a pharmaceutically acceptable salt thereof. The compounds provided herein can be useful for treatment or prevention of diseases including heart (e.g. ischemic heart disease, congestive heart failure, and valvular heart disease), lung (e.g., lung inflammation, pneumonia, acute lung injury, pulmonary hypertension, pulmonary fibrosis, and chronic obstructive pulmonary disease), respiratory (e.g.,respiratory infection, acute respiratory distress syndrome), liver (e.g. acute liver failure and liver fibrosis and cirrhosis), and kidney (e.g. acute kidney injury and chronic kidney disease) disease, inflammatory bowel disease (IBD), ischemic reperfusion injury (e.g., stroke), retinopathy of prematurity (ROP), bronchopulmonary dysplasia (BPD), and white matter injury (WMI).

The invention relates to the technical field of medical care, in particular to an intelligent early warning system for dynamic deterioration of chronic obstructive pulmonary disease, which is used for solving the technical problem of inaccurate evaluation of lung ventilation capability of a user in the prior art. The system comprises a data acquisition unit used for acquiring lung function time sequence data and multi-dimensional physiological time sequence data of a target user in an observation stage; the observation phase comprises a plurality of consecutive dates; the processing unit is used for determining suspected abnormal days according to the lung function time sequence data, determining the deviation degree of the multi-dimensional physiological time sequence data of the suspected abnormal days and the multi-dimensional physiological time sequence data of the reference day and the similarity of the deviation degree of the physiological time sequence data of different dimensions, determining the abnormal days from the suspected abnormal days based on the deviation degree and the similarity, and sending the abnormal days to the user. The chronic obstructive pulmonary disease dynamic deterioration risk level of the target user is determined based on the abnormal days; and performing risk early warning based on the chronic obstructive pulmonary disease dynamic deterioration risk level of the target user.

The present application relates to the technical field of health care, in particular to an intelligent early warning system for dynamic exacerbation of chronic obstructive pulmonary disease, which is used to solve the technical problem of inaccurate assessment of lung ventilation capacity of users in the prior art. The system comprises: a data acquisition unit for acquiring lung function time series data and multi-dimensional physiological time series data of a target user in an observation period; the observation period comprises a plurality of consecutive days; a processing unit for determining suspected abnormal days according to the lung function time series data, determining the deviation degree of the multi-dimensional physiological time series data of the suspected abnormal days and the multi-dimensional physiological time series data of the reference days and the similarity of the different dimensional physiological time series data deviation degrees, determining the abnormal days from the suspected abnormal days based on the deviation degree and the similarity, and determining the dynamic exacerbation risk level of the target user's chronic obstructive pulmonary disease based on the abnormal days; and performing risk warning based on the dynamic exacerbation risk level of the target user's chronic obstructive pulmonary disease.

This disclosure relates to a method, system, and dynamic X-ray camera for intelligent identification of chronic obstructive pulmonary disease (COPD), belonging to the field of intelligent COPD identification technology. The intelligent COPD identification method includes: acquiring one or more of the following dynamic X-ray quantitative parameters from a sequence of left lung field area parameters, right lung field area parameters, left diaphragm parameters, right diaphragm parameters, and cardiothoracic ratio parameters corresponding to multiple dynamic two-dimensional chest X-ray images during respiration; and performing intelligent COPD identification based on one or more of the dynamic X-ray quantitative parameters from the left lung field area parameters, right lung field area parameters, left diaphragm parameters, right diaphragm parameters, and cardiothoracic ratio parameters, using a preset intelligent COPD identification model. The embodiments of this disclosure can achieve intelligent identification of chronic obstructive pulmonary disease.

The present application relates to use of a heterocyclic compound in the treatment of a pulmonary disease, and specifically to use of a heterocyclic compound in the treatment of chronic obstructive pulmonary disease (COPD).

Respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD) are commonly treated with β2-adrenergic receptor agonists that activate intracellular signaling pathways to induce airway relaxation. However, current therapies are limited by progressive receptor desensitization, or tachyphylaxis, largely attributed to β-arrestin recruitment. This desensitization reduces therapeutic efficacy over time and complicates long-term disease management, resulting in suboptimal outcomes for patients who rely on bronchodilators for daily symptom control. Disclosed herein are pharmaceutical compositions comprising biased agonists and their methods of use, which minimally activate recruitment of beta-arrestin2.

The application relates to a method for constructing a rat model of chronic obstructive pulmonary disease (COPD) related pulmonary arterial hypertension and application thereof, and belongs to the technical field of animal disease model construction. The method selects 6-8-week-old, 220+ / -10g healthy male SD rats, and all the rats are adaptively fed in a standard SPF level animal room for 7 days; then the rats are divided into a Con group and a COPD-PH group; the rats in the COPD-PH group are given 1mg / mL lipopolysaccharide by airway instillation on the first day and the 14th day; the rats are placed in a self-made whole-body inhalation smoking box for 1h every day from the 2nd day to the 13th day and from the 15th day to the 30th day; the rats enter a low-oxygen box for 8h every day during the light period from the 2nd day to the 13th day and from the 15th day to the 30th day; the rat model can simultaneously reproduce the characteristics of COPD and typical changes of pulmonary arterial hypertension, the right ventricular systolic pressure can be stably increased to 40-50mmHg, the right ventricular hypertrophy index can reach 0.40-0.50, the pulmonary vascular remodeling and inflammation are significant, and various indexes are stable and good in repeatability.

This invention belongs to the field of biomedical technology, specifically relating to a rapid purification method for umbilical cord MSC exosomes and their application in the preparation of drugs for treating COPD. This invention discloses a method for rapidly purifying umbilical cord mesenchymal stromal cell (MSC) exosomes and a pharmaceutical composition comprising umbilical cord MSC exosomes and yamosaponin. In this pharmaceutical composition, the umbilical cord MSC exosomes and yamosaponin synergistically enhance the dynamic compliance of COPD rats, reduce airway resistance, decrease pulmonary inflammation, and repair pulmonary dysfunction. This invention provides a new technical solution for the preparation of drugs for treating or improving COPD.

The application provides a recovery training device for chronic obstructive pulmonary disease, and belongs to the technical field of recovery training for chronic obstructive pulmonary disease. The recovery training device for chronic obstructive pulmonary disease comprises a base, a training mechanism is arranged on the top of the base, the training mechanism comprises an installation plate and a first training ball, the installation plate is fixedly arranged on the top of the base, the installation plate is provided with two, the top of each of the two installation plates is fixedly provided with a first training cylinder and a second training cylinder. The training mechanism is arranged, when performing exhalation training, the user blows, the gas in the blowing pipe lifts the first training ball upward, and when the first training ball reaches the top of the first training cylinder, the user stops blowing, and the first training ball falls due to gravity; when performing inhalation training, the user inhales, a negative pressure is generated in the second training cylinder at this time, the second training ball moves upward, so that the user can conveniently perform inhalation and blowing training.

The present invention relates to novel heterocyclic compounds useful in the preparation of medicaments for the treatment of diseases associated with various functions of the histamine 4 receptor.In particular, said drugs are useful for treating inflammatory diseases, allergy, pain, nasal polyps, rhinitis, chronic sinusitis, nasal congestion, nasal itching, asthma, chronic obstructive pulmonary disease, rheumatoid arthritis, atopic dermatitis, psoriasis, eczema, pruritus, itchy skin, urticaria, idiopathic chronic urticaria, scleroderma, conjunctivitis, keratoconjunctivitis, ocular inflammation, dry eye, cardiac dysfunction, arrhythmia, atherosclerosis, multiple sclerosis, inflammatory bowel disease (including colitis, Crohn's disease, ulcerative colitis), inflammatory pain, neuropathic pain, osteoarthritis pain, autoimmune disease, thyroid, immune-mediated (also known as type I) diabetes, lupus, post-surgical adhesions, vestibular disorders and cancer.

Disclosed is a synthetic, non-naturally occurring 12-amino acid peptide, Lung-specific Targeting Peptide, belonging to the larger class of cell penetrating peptides, for delivery of both diagnostic and potentially therapeutic agents to the lung. Also disclosed are methods of treating pulmonary disease, e.g., chronic obstructive pulmonary disease (COPD), emphysema, chronic bronchitis, asthma, primary ciliary dyskinesia (PCD), cystic fibrosis (CF), and lung cancer.

The present invention relates to an antisense oligonucleotide targeting an interleukin 4 receptor and the use thereof. The antisense oligonucleotide (ASO) molecule has a length of 16-22 bases and is specifically paired with a specific region of a target gene (interleukin 4 receptor). The ASO is used for treating diseases associated with IL-4Rα, which includes, but is not limited to, asthma (including eosinophilic asthma), atopic dermatitis, eosinophilic esophagitis, sinusitis, nasal polyps, prurigo nodularis, urticaria, chronic obstructive pulmonary disease, bullous pemphigoid, pruritus, and gastritis.

The invention discloses application of a marker to preparation of a kit for diagnosing chronic obstructive pulmonary diseases. According to the application disclosed by the invention, the accuracy of diagnosing the chronic obstructive pulmonary disease by using (R)-3-hydroxytetradecanoic acid alone or in combination with the azelayl platelet activating factor is relatively high; on the basis of combination of (R)-3-hydroxytetradecanoic acid and an azelayl platelet activating factor, the compound is prepared. The compound can be further combined with one or two of 1-hexadecyl-2-(5-oxovaleryl)-sn-glycerol-3-phosphorylcholine, 1-O-hexadecyl-SN-glycerol-3-choline phosphoric acid, lauroyl-L-carnitine and beta-acetyl-gamma-O-alkyl-L-alpha-phosphatidylcholine to be used for diagnosing the chronic obstructive pulmonary disease. Therefore, a diagnostic kit for diagnosing the chronic obstructive pulmonary disease can be prepared on the basis of the scheme, and the kit contains a compound standard substance corresponding to the scheme and can also contain an internal standard compound for mass spectrum quantitative analysis.

The application provides application of dimethyl carbonate as a chronic obstructive pulmonary disease diagnostic marker and belongs to the technical field of biomedical detection. The application first finds that the detection rate of dimethyl carbonate in exhaled air is significantly related to chronic obstructive pulmonary disease, and the detection rate of dimethyl carbonate in exhaled air of a chronic obstructive pulmonary disease patient is significantly higher than that of a healthy person. The ROC curve analysis result shows that dimethyl carbonate has extremely high specificity as a biomarker for diagnosing chronic obstructive pulmonary disease, and therefore can be used as a detection target for the diagnosis of chronic obstructive pulmonary disease patients, and has good practical application value.

The present disclosure, relates, in general, to methods of treating chronic obstructive pulmonary disease (COPD) using an antibody specific for thymic stromal lymphopoietin (TSLP).

This invention relates to a guinea pig model of chronic obstructive pulmonary disease (COPD) with chronic bronchitis, its preparation method, and its application. Specifically, this invention provides a guinea pig model of COPD with chronic bronchitis, established by subjecting guinea pigs to at least two intratracheal infusions of lipopolysaccharide (LPS) combined with repeated exposure to cigarette smoke. This results in the guinea pigs exhibiting pathophysiological characteristics consistent with those of COPD with chronic bronchitis in terms of cough sensitivity, airway inflammation, airway hypersecretion, lung function, and histopathology. This lays a solid foundation for in-depth research and drug screening of COPD with chronic bronchitis.